| Use of cytomegalovirus hyperimmunoglobulin for prevention of congenital cytomegalovirus disease: a retrospective analysis. | |
| | |
MedLine Citation:
|
PMID: 22752777 Owner: NLM Status: In-Data-Review |
Abstract/OtherAbstract:
|
Abstract Aims: The aim of this study was to investigate the current prenatal "off-label use" of cytomegalovirus hyperimmunoglobulin (CMV-HIG) in the prevention and treatment of congenital CMV (cCMV) infection, including the long-term outcome of the children. Methods: This retrospective observational study comprised mothers and their children, born between January 1, 2006, and October 30, 2010. Prenatal CMV-HIG was administered after diagnosis of primary CMV infection of the mother. Clinical and virological data were collected from maternal and pediatric medical and laboratory reports. Follow-up was 12-36 months after birth. Results: Forty-two women and 43 children met the study criteria. In total, 40 mothers and six unborn infants received 115 doses of CMV-HIG. The treatment group (TG; CMV-DNA polymerase chain reaction-positive amniotic fluid) included four mothers; the multinomial group (MG; CMV-positive mother and unknown CMV status of fetus) included 38 mothers (39 infants). For the four unborn infants in TG, CMV-HIG was administered either intraumbilically or into the amniotic fluid; three of the four mothers received intravenous CMV-HIG. Three children in TG remained CMV-positive and were asymptomatic at birth and during follow-up. One infant in TG had symptomatic cCMV infection in utero, at birth, and during follow-up. In MG, 37 of 38 women received intravenous CMV-HIG and two of 39 infants received CMV-HIG in utero. In total, 9 (23.1%) of 39 children in MG were positive for cCMV (including a terminated pregnancy). All eight instances of cCMV infection at birth in MG were asymptomatic at birth and during follow-up. The fetus from the terminated pregnancy showed no sonographic symptoms of cCMV infection. No severe side effect occurred in 115 CMV-HIG applications. Conclusion: CMV-HIG was well tolerated. Compared with published untreated mother-child pairs, we observed a trend toward a smaller risk for intrauterine CMV transmission following CMV-HIG application. Signs of prenatal cCMV disease were not reversed after CMV-HIG. |
| | |
Authors:
|
Horst Buxmann; Otto M V Stackelberg; Rolf L Schlößer; Gisela Enders; Markus Gonser; Matthias Meyer-Wittkopf; Klaus Hamprecht; Martin Enders |
Related Documents
:
|
10381227 - Perinatal epstein barr virus infection in a premature infant. 11774017 - Neonatal varicella. 6324227 - Effects of folic acid malnutrition on rotaviral infection in mice. 9726347 - Outbreak of acinetobacter spp. bloodstream infections in a nursery associated with cont... 22972077 - Late erythropoietin for preventing red blood cell transfusion in preterm and/or low bir... 3439947 - Hydrops foetalis in sheep. |
Publication Detail:
|
Type: Journal Article Date: 2012-03-27 |
Journal Detail:
|
Title: Journal of perinatal medicine Volume: 40 ISSN: 1619-3997 ISO Abbreviation: J Perinat Med Publication Date: 2012 |
Date Detail:
|
Created Date: 2012-07-03 Completed Date: - Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 0361031 Medline TA: J Perinat Med Country: Germany |
Other Details:
|
Languages: eng Pagination: 439-46 Citation Subset: IM |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
|
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: An open-label, randomized efficacy and safety trial of subcutaneous and intramuscular BT088 (Fovepta...
Next Document: Therapeutic hypothermia and hypoxic ischemic encephalopathy: opinion and practice of pediatricians i...